Core Viewpoint - Sanofi (NASDAQ:SNY) is identified as an undervalued stock under $50, particularly following the FDA's Breakthrough Therapy designation for its investigational drug, venglustat, aimed at treating neurological manifestations of type 3 Gaucher disease [1]. Group 1: FDA Designation and Study Results - The FDA granted Breakthrough Therapy designation to venglustat based on data from the LEAP2MONO phase 3 study, which showed significant improvements in neurological symptoms compared to enzyme replacement therapy [2]. - Venglustat was well tolerated in the study, with no new safety signals reported compared to previous studies [2]. Group 2: Adverse Events and Regulatory Plans - Commonly reported adverse events for venglustat included headache, nausea, diarrhea, and spleen enlargement [3]. - Sanofi plans to pursue global regulatory filings for venglustat in 2026 for its use in treating Gaucher disease type 3 [3]. Group 3: Company Overview - Sanofi is involved in the research, production, and distribution of pharmaceutical products, with operations segmented into Pharmaceuticals, Consumer Healthcare, and Vaccines [4].